Literature DB >> 2205002

Fragments of the HIV-1 Tat protein specifically bind TAR RNA.

K M Weeks1, C Ampe, S C Schultz, T A Steitz, D M Crothers.   

Abstract

Proteolytically produced carboxyl-terminal fragments of the human immunodeficiency virus type-1 (HIV-1) Tat protein that include a conserved region rich in arginine and lysine bind specifically to transactivation response RNA sequences (TAR). A chemically synthesized 14-residue peptide spanning the basic subdomain also recognizes TAR, identifying this subdomain as central for RNA interaction. TAR RNA forms a stable hairpin that includes a six-residue loop, a trinucleotide pyrimidine bulge, and extensive duplex structure. Competition and interference experiments show that the Tat-derived fragments bind to double-stranded RNA and interact specifically at the pyrimidine bulge and adjacent duplex of TAR.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2205002     DOI: 10.1126/science.2205002

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  164 in total

1.  Molecular dynamics studies of the HIV-1 TAR and its complex with argininamide.

Authors:  R Nifosì; C M Reyes; P A Kollman
Journal:  Nucleic Acids Res       Date:  2000-12-15       Impact factor: 16.971

2.  Identification of ligands for RNA targets via structure-based virtual screening: HIV-1 TAR.

Authors:  A V Filikov; V Mohan; T A Vickers; R H Griffey; P D Cook; R A Abagyan; T L James
Journal:  J Comput Aided Mol Des       Date:  2000-08       Impact factor: 3.686

3.  Tobacco calmodulin-like protein provides secondary defense by binding to and directing degradation of virus RNA silencing suppressors.

Authors:  Kenji S Nakahara; Chikara Masuta; Syouta Yamada; Hanako Shimura; Yukiko Kashihara; Tomoko S Wada; Ayano Meguro; Kazunori Goto; Kazuki Tadamura; Kae Sueda; Toru Sekiguchi; Jun Shao; Noriko Itchoda; Takeshi Matsumura; Manabu Igarashi; Kimihito Ito; Richard W Carthew; Ichiro Uyeda
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

4.  In vitro selection of ribozymes dependent on peptides for activity.

Authors:  Michael P Robertson; Scott M Knudsen; Andrew D Ellington
Journal:  RNA       Date:  2004-01       Impact factor: 4.942

Review 5.  How the phage lambda N gene product suppresses transcription termination: communication of RNA polymerase with regulatory proteins mediated by signals in nascent RNA.

Authors:  A Das
Journal:  J Bacteriol       Date:  1992-11       Impact factor: 3.490

6.  An adenosine at position 27 in the human immunodeficiency virus type 1 trans-activation response element is not critical for transcriptional or translational activation by Tat.

Authors:  A D Blanchard; R Powell; M Braddock; A J Kingsman; S M Kingsman
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

7.  Circular dichroism and molecular modeling yield a structure for the complex of human immunodeficiency virus type 1 trans-activation response RNA and the binding region of Tat, the trans-acting transcriptional activator.

Authors:  E P Loret; P Georgel; W C Johnson; P S Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

8.  Loop-loop interaction of HIV-1 TAR RNA with N3'-->P5' deoxyphosphoramidate aptamers inhibits in vitro Tat-mediated transcription.

Authors:  Fabien Darfeuille; Andrey Arzumanov; Sergei Gryaznov; Michael J Gait; Carmelo Di Primo; Jean-Jacques Toulmé
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-08       Impact factor: 11.205

Review 9.  Fluorescent indicator displacement assays to identify and characterize small molecule interactions with RNA.

Authors:  Sarah L Wicks; Amanda E Hargrove
Journal:  Methods       Date:  2019-04-30       Impact factor: 3.608

10.  Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein.

Authors:  T C Rodman; S E To; H Hashish; K Manchester
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.